What a difference ADA2 makes: Insights into the pathophysiology of ADA2 deficiency from single-cell RNA sequencing of monocytes

Lisa Ehlers; Isabelle Meyts

doi:10.1002/JLB.5CE0421-186R

What a difference ADA2 makes: Insights into the pathophysiology of ADA2 deficiency from single-cell RNA sequencing of monocytes

J Leukoc Biol. 2021 Sep;110(3):405-407. doi: 10.1002/JLB.5CE0421-186R. Epub 2021 Jun 16.

Authors

Lisa Ehlers¹, Isabelle Meyts²

Affiliations

¹ Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany.
² Department of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium.

PMID: 34137068
DOI: 10.1002/JLB.5CE0421-186R

Abstract

Discussion on the increase in nonclassical monocytes in patients with DADA2 as shown by scRNA seq; these pro inflammatory cells also show increased TNFR2, type I, and type II IFN pathway gene expression.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adenosine Deaminase* / genetics
Humans
Intercellular Signaling Peptides and Proteins
Monocytes*
Mutation
Sequence Analysis, RNA

Substances

Intercellular Signaling Peptides and Proteins
Adenosine Deaminase